JP2020045328A - ガロカテキンの使用 - Google Patents
ガロカテキンの使用 Download PDFInfo
- Publication number
- JP2020045328A JP2020045328A JP2019053867A JP2019053867A JP2020045328A JP 2020045328 A JP2020045328 A JP 2020045328A JP 2019053867 A JP2019053867 A JP 2019053867A JP 2019053867 A JP2019053867 A JP 2019053867A JP 2020045328 A JP2020045328 A JP 2020045328A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- control
- formula
- increasing
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 title abstract description 5
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 title abstract description 5
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 title abstract description 5
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 title abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 43
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229960003987 melatonin Drugs 0.000 claims abstract description 40
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 40
- 230000001965 increasing effect Effects 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 20
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 19
- 230000028327 secretion Effects 0.000 claims abstract description 15
- 230000028993 immune response Effects 0.000 claims abstract description 11
- 230000002439 hemostatic effect Effects 0.000 claims abstract description 10
- 230000036651 mood Effects 0.000 claims abstract description 10
- 206010047139 Vasoconstriction Diseases 0.000 claims abstract description 9
- 230000025033 vasoconstriction Effects 0.000 claims abstract description 9
- 230000001737 promoting effect Effects 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 44
- 230000014509 gene expression Effects 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 235000013305 food Nutrition 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 17
- 208000019116 sleep disease Diseases 0.000 claims description 12
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 11
- 101150058700 Tph1 gene Proteins 0.000 claims description 10
- 101150102279 ddc gene Proteins 0.000 claims description 10
- 206010022437 insomnia Diseases 0.000 claims description 10
- 230000007958 sleep Effects 0.000 claims description 10
- 101150071927 AANAT gene Proteins 0.000 claims description 9
- 101150028660 ASMTL gene Proteins 0.000 claims description 9
- 238000010253 intravenous injection Methods 0.000 claims description 7
- 238000010254 subcutaneous injection Methods 0.000 claims description 7
- 239000007929 subcutaneous injection Substances 0.000 claims description 6
- 235000021407 appetite control Nutrition 0.000 claims description 5
- 230000006806 disease prevention Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 abstract description 5
- 230000036528 appetite Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 description 22
- 230000001276 controlling effect Effects 0.000 description 18
- 235000015872 dietary supplement Nutrition 0.000 description 13
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 102100030547 Serotonin N-acetyltransferase Human genes 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 7
- 101000652292 Homo sapiens Serotonin N-acetyltransferase Proteins 0.000 description 7
- 101000830742 Homo sapiens Tryptophan 5-hydroxylase 1 Proteins 0.000 description 7
- 101710111485 N-acetylserotonin O-methyltransferase-like protein Proteins 0.000 description 7
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 description 7
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 7
- 235000013402 health food Nutrition 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000035790 physiological processes and functions Effects 0.000 description 6
- 229940076279 serotonin Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000004560 pineal gland Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- -1 aromatic amine amino acid Chemical class 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010074515 Arylalkylamine N-Acetyltransferase Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- MVAWJSIDNICKHF-UHFFFAOYSA-N N-acetylserotonin Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CNC2=C1 MVAWJSIDNICKHF-UHFFFAOYSA-N 0.000 description 1
- 102100027445 N-acetylserotonin O-methyltransferase-like protein Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 206010041347 Somnambulism Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000003752 hydrotrope Substances 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000000793 pinealocyte Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 235000000053 special nutrition Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000016776 visual perception Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明はまた、神経代謝障害に関連する疾患の治療、神経代謝障害に関連する疾患の予防、食欲制御、気分制御、血管収縮制御、止血機能制御、および/または免疫応答制御における、式(I)の化合物の使用に関する。本発明はまた、TPH1遺伝子発現の増加、DDC遺伝子発現の増加、AANAT遺伝子発現の増加、および/またはASMTL遺伝子発現の増加における、式(I)の化合物の使用に関する。
本出願は、2018年9月19日に台湾経済部知的財産局へ出願された台湾特許出願第107133010号の優先権を主張するものであり、その開示は、参照によりその全体が本明細書に組み込まれる。
好ましくは、医薬組成物は、経口投与、経皮投与、静脈内注射、または皮下注射の形態で提供される。好ましくは、医薬組成物は、不眠治療用である。
好ましくは、本発明の方法は、不眠の治療、睡眠障害の改善、および睡眠制御のためのものである。本発明による方法において、式(I)の化合物を上述の医薬組成物として投与することができる。
したがって、本発明は、睡眠障害改善、食欲制御、睡眠制御、気分制御、血管収縮制御、止血機能制御、および/または免疫応答制御において式(I)の化合物を使用すること、医薬組成物の製造において式(I)の化合物を使用すること、ならびに有効量の式(I)の化合物を必要とする対象に投与する方法を提供することを含む、式(I)の化合物の使用に関する。本発明に従って提供される医薬組成物および方法はまた、TPH1遺伝子、DDC遺伝子、AANAT遺伝子、および/またはASMTL遺伝子の発現を増加させるためのものでもある。
1.本発明の式(I)の化合物:ChemFaces社(Rainbow Biotechnology CO., LTD)より購入、製品番号:CFN99137、CAS番号:3371−27−5。
2.SHSY5Y細胞:ATCCより購入、製品番号:CRL−2266。
3.DMEM培地:90%DMEM、10%FBS、および1%ペニシリン/ストレプトマイシン含有;DMEMはGibcoより購入(製品番号:12100−046)、FBSはGibcoより購入(製品番号:10437−028)、およびペニシリン/ストレプトマイシンはGibcoより購入。
4.RNA抽出キット:Geneaidより購入。
5.逆転写酵素(SuperScript(登録商標)III逆転写酵素):Invitrogen社より購入。
6.KAPA SYBR FAST qPCRキット:KAPA Biosystems社より購入。
7.Step One Plusシステム:ABI社より購入。
1.対照群:DMEM培地;
2.実験群:対照群と同様の培地に、0.0625μg/mlの式(I)の化合物を加えたもの。
Claims (7)
- メラトニン合成の増加、メラトニン分泌の促進、神経代謝障害に関連する疾患の治療、神経代謝障害に関連する疾患の予防、食欲制御、気分制御、血管収縮制御、止血機能制御、および免疫応答制御のうち少なくとも1つのための組成物であって、以下の式(I)の化合物を含んでなる組成物:
- 前記式(I)の化合物が、経口投与、経皮投与、静脈内注射、および皮下注射のうち少なくとも1つによって投与される請求項1に記載の組成物。
- 前記組成物が医薬組成物であり、かつメラトニン合成の増加、メラトニン分泌の促進、神経代謝障害に関連する疾患の治療、および神経代謝障害に関連する疾患の予防のうち少なくとも1つのための組成物である請求項1に記載の組成物。
- 不眠を治療するための組成物である請求項3に記載の組成物。
- 前記組成物が食品組成物であり、かつ睡眠障害改善、ならびに睡眠制御、食欲制御、気分制御、血管収縮制御、止血機能制御、および免疫応答制御のうち少なくとも1つのための組成物である請求項1に記載の組成物。
- TPH1遺伝子発現の増加、DDC遺伝子発現の増加、AANAT遺伝子発現の増加、およびASMTL遺伝子発現の増加のうち少なくとも1つのための組成物であって、以下の式(I)の化合物を含んでなる組成物:
- 前記式(I)の化合物が、経口投与、経皮投与、静脈内注射、および皮下注射のうち少なくとも1つによって投与される請求項6に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762590129P | 2017-11-22 | 2017-11-22 | |
TW107133010 | 2018-09-19 | ||
TW107133010A TWI670059B (zh) | 2017-11-22 | 2018-09-19 | 沒食子兒茶素之應用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020045328A true JP2020045328A (ja) | 2020-03-26 |
JP6807423B2 JP6807423B2 (ja) | 2021-01-06 |
Family
ID=67348104
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019053867A Active JP6807423B2 (ja) | 2017-11-22 | 2019-03-20 | ガロカテキンの使用 |
JP2019053868A Active JP6840178B2 (ja) | 2017-11-22 | 2019-03-20 | ヒドロキシアニゴルホンの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019053868A Active JP6840178B2 (ja) | 2017-11-22 | 2019-03-20 | ヒドロキシアニゴルホンの使用 |
Country Status (4)
Country | Link |
---|---|
US (3) | US10646466B2 (ja) |
JP (2) | JP6807423B2 (ja) |
CN (2) | CN109806257A (ja) |
TW (2) | TWI670059B (ja) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3517274B2 (ja) | 1994-05-20 | 2004-04-12 | 株式会社ナリス化粧品 | 皮膚組成物 |
GB9808796D0 (en) | 1998-04-24 | 1998-06-24 | Rowett Research Services Limit | Antithrombotic agents |
US20070298133A1 (en) * | 2006-06-23 | 2007-12-27 | The Procter & Gamble Company | Compositions and kits comprising a melatonin component and a flavanol component |
US20100028469A1 (en) | 2008-06-04 | 2010-02-04 | Herbalscience Group, Llc | Extracts of Cranberry and Methods of Using Thereof |
KR20120095352A (ko) | 2009-08-12 | 2012-08-28 | 무니색하 매다사니 | 전체 바나나 열매 (musa spp.)로부터의 천연 추출물 |
CN101824021B (zh) * | 2009-10-14 | 2013-01-09 | 南开大学 | 莲藕中儿茶素类小分子的提取方法及其应用 |
JP6412291B1 (ja) | 2017-01-20 | 2018-10-24 | マルカイコーポレーション株式会社 | 頻尿の改善剤 |
-
2018
- 2018-09-19 TW TW107133010A patent/TWI670059B/zh active
- 2018-09-20 CN CN201811101637.4A patent/CN109806257A/zh active Pending
- 2018-10-08 TW TW107135407A patent/TWI657817B/zh active
- 2018-10-10 CN CN201811176612.0A patent/CN109806248A/zh active Pending
- 2018-11-06 US US16/182,158 patent/US10646466B2/en active Active
- 2018-11-09 US US16/185,429 patent/US10646455B2/en active Active
-
2019
- 2019-03-20 JP JP2019053867A patent/JP6807423B2/ja active Active
- 2019-03-20 JP JP2019053868A patent/JP6840178B2/ja active Active
-
2020
- 2020-01-29 US US16/776,190 patent/US10905674B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2020059691A (ja) | 2020-04-16 |
JP6840178B2 (ja) | 2021-03-10 |
US10646466B2 (en) | 2020-05-12 |
US20200163907A1 (en) | 2020-05-28 |
US10646455B2 (en) | 2020-05-12 |
CN109806248A (zh) | 2019-05-28 |
JP6807423B2 (ja) | 2021-01-06 |
TW201924671A (zh) | 2019-07-01 |
US20190151281A1 (en) | 2019-05-23 |
US10905674B2 (en) | 2021-02-02 |
TW201924666A (zh) | 2019-07-01 |
US20190151257A1 (en) | 2019-05-23 |
CN109806257A (zh) | 2019-05-28 |
TWI670059B (zh) | 2019-09-01 |
TWI657817B (zh) | 2019-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2946825C (en) | Muscle atrophy inhibitor containing quercetin glycoside | |
EP1001760B1 (en) | Composition for controlling mood disorders in healthy individuals | |
KR20090097922A (ko) | 스테로이드 요법에 있어서의 부작용의 개선·억제용 조성물 | |
JP5271534B2 (ja) | 筋萎縮抑制剤 | |
CN112121034B (zh) | 叶黄素用于治疗癌症的用途 | |
JP6807423B2 (ja) | ガロカテキンの使用 | |
KR20200038408A (ko) | IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 근감소증의 예방 또는 치료용 약학 조성물 | |
JP2010241827A (ja) | 5−ヒドロキシトリプタミン1aレセプター活性増強化合物を用いる運動症状の変動の治療 | |
KR101671008B1 (ko) | TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 식욕억제용 약학적 조성물 | |
JP2007176804A (ja) | 痩身作用を有する医薬又は健康食品 | |
CN115867270A (zh) | 烟酰胺腺嘌呤二核苷酸(nad)浓度上升剂 | |
KR102208654B1 (ko) | Tph1 유전자, ddc 유전자 및/또는 aanat 유전자의 발현을 조절하기 위한 바나나 껍질 추출물을 포함하는 조성물 | |
KR20210097487A (ko) | 후코이단을 포함하는 수면장애 예방, 개선 또는 치료용 조성물 | |
US20220023393A1 (en) | Pharmaceutical composition for preventing or treating obesity or sarcopenia, containing if1 as active ingredient | |
US20230025468A1 (en) | Method and a dietary composition on regulation, treatment, and prevention of obesity | |
JP2006117550A (ja) | 破骨細胞分化抑制因子産生促進剤 | |
US20230024207A1 (en) | Method and a dietary composition on regulation, treatment, and prevention of obesity | |
WO2008001495A1 (fr) | Agent contre les contraintes psychosociales | |
JP6706852B2 (ja) | 細胞老化抑制剤 | |
EP1964558A1 (en) | Pharmaceutical compositions containing intestinal lipase inhibiting substances combined with a chromium dinicotinate o-coordinated complex for use in the treatment and control of obesity and overweight | |
Stucky et al. | Studies in the Physiology of Vitamins: VI. The Effect of Insulin on Gastric Motility in Vitamin B Deficiency | |
JP6216913B1 (ja) | 医薬組成物 | |
WO2010098475A1 (ja) | 摂食障害予防及び治療剤 | |
JP2021038147A (ja) | ミトコンドリア生合成促進剤 | |
WO2014030624A1 (ja) | スチルベン誘導体を有効成分として含有する筋緊張性ジストロフィー治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200511 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200722 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200831 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201120 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201207 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6807423 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |